Reporter Gene mRNA Synthesis Service
In the rapidly evolving landscape of therapeutic nucleic acid development, the ability to visualize and quantify gene delivery efficiency is paramount. CD BioGlyco provides a premier reporter gene mRNA synthesis service, designed to empower researchers with high-purity, ready-to-transfect messenger RNA (mRNA) molecules. Reporter genes serve as indispensable tools in biotechnology, acting as surrogate markers that reflect the successful uptake and translation of nucleic acid cargo within target cells. Our service bridges the gap between complex molecular design and functional biological validation. By synthesizing mRNA encoding well-characterized proteins such as firefly luciferase, enhanced green fluorescent protein, and beta-galactosidase (β-Gal), we enable real-time monitoring of gene expression kinetics and spatial distribution. Whether you are optimizing a lipid nanoparticle (LNP) formulation or evaluating a novel tissue-specific promoter, our reporter gene mRNA solutions provide the clarity and precision required for data-driven decisions.
Key Technologies
Advanced In Vitro Transcription (IVT)
We utilize high-fidelity T7 RNA polymerase systems optimized for high-yield production. Our IVT service is engineered to minimize the generation of double-stranded RNA (dsRNA) by-products, which are known to trigger innate immune responses via toll-like receptors (TLRs).
Precision Co-Transcriptional Capping
To ensure maximum translation efficiency and transcript stability, we employ advanced capping technologies, including the anti-reverse cap analog. These technologies yield a cap-1 structure that mimics natural eukaryotic mRNA, significantly enhancing in vivo performance.
Custom Nucleotide Modification
We offer comprehensive chemical modification options, such as the incorporation of N1-methylpseudouridine or 5-methoxyuridine. These modifications are strategically used to reduce immunogenicity and increase the half-life of the reporter protein expression.
From Sequence to Signal: Your Partner in High-Performance Reporter mRNA Solutions
As a critical component of our therapeutic nucleic acid development platform, the reporter gene mRNA synthesis service at CD BioGlyco is tailored to meet the rigorous demands of both academic research and industrial drug discovery. Our scope encompasses the production of a wide array of reporter constructs:
- Bioluminescent Reporters: Synthesis of mRNA for firefly luciferase and Renilla luciferase. These are ideal for highly sensitive, quantitative assays in deep-tissue in vivo imaging or high-throughput screening (HTS).
- Fluorescent Reporters: Production of high-quality transcripts for enhanced green fluorescent protein and eYFP. These allow for analysis via flow cytometry or confocal microscopy.
- Enzymatic Reporters: Synthesis of mRNA encoding beta-galactosidase or secreted embryonic alkaline phosphatase (SEAP) for colorimetric or chemiluminescent detection.
- Custom ORF Integration: Beyond standard reporters, we can synthesize mRNA containing your specific gene of interest (GOI) fused with a reporter tag, facilitating the study of protein localization and stability.
Workflow
Template Design and Plasmid Construction
The process begins with the optimization of the DNA template. We design the 5' and 3' untranslated regions (UTRs) to maximize translation efficiency and include a poly-A tail of optimal length (typically 100-120 nucleotides) to prevent exonuclease degradation.
Plasmid Linearization and Quality Control (QC)
The circular DNA template is linearized using high-specificity restriction enzymes. We perform rigorous QC using agarose gel electrophoresis and sequence verification to ensure the template is "clean" and accurate.
Optimized In Vitro Transcription
The linearized DNA undergoes IVT in a controlled environment. During this stage, we incorporate modified nucleotides and capping analogs according to the client's specific requirements to achieve the desired biological profile.
Enzymatic DNA Digestion and Clean-up
Following synthesis, the DNA template is removed using DNase I. We then employ advanced purification techniques, such as lithium chloride precipitation or spin-column chromatography, to remove residual enzymes, free nucleotides, and short abortive transcripts.
Stringent mRNA Purification
For applications requiring ultra-low immunogenicity, we offer high-performance liquid chromatography (HPLC) or fast protein liquid chromatography (FPLC) purification. This step is crucial for removing dsrna contaminants that interfere with experimental results.
Comprehensive Analytical Validation
Every batch of reporter gene mRNA undergoes a final battery of tests, including fragment analyzer or bioanalyzer assessment for integrity, nanodrop for concentration, and endotoxin testing to ensure compatibility with sensitive cell types and in vivo models.
Publication Data
DoI: 10.3390/cells12222596
Journal: Cells
IF: 5.2
Published: 2023
Results: This article presents a reporter gene-based quantitative real-time PCR (qRT-PCR) assay to detect Rho-dependent termination (RDT) and Rho-independent termination (RIT) in vivo. Due to biases in reverse transcription and PCR amplification, direct measurement of RDT sites is challenging. The researchers used a 77 bp argX gene (coding tRNAarg) from Brevibacterium albidum as the reporter, fusing it with gal operon sequences containing or lacking RDT/RIT regions to construct plasmids. By quantifying tRNAarg levels via qRT-PCR (with consistent tRNAarg degradation rates ensuring reliability), they determined RDT efficiencies at galET (36%), galTK (26%), and galM end (63%), and RIT efficiency at gal operon end (33%). This method avoids translation bias and exogenous substrates, offering a reliable, quantitative tool for studying bacterial transcription termination.
Fig.1 Plasmids used to measure RDT efficiency in vivo and their construction strategy. (N, et al., 2023)
Applications
Drug Delivery System (DDS) Evaluation
Testing the efficiency of LNPs, polymers, or viral vectors in delivering nucleic acid cargo to specific organs.
Vaccine Development
Assessing the translation efficiency of mrna vaccine platforms in various tissue environments.
Cell Therapy Research
Monitoring the persistence and expression levels of transcripts in chimeric antigen receptor (CAR) T-cells or stem cells.
Gene Regulation Studies
Investigating the impact of different UTR sequences or chemical modifications on protein production kinetics.
Advantages
Exceptional Purity
Our specialized purification protocols eliminate dsRNA and other impurities, ensuring a high signal-to-noise ratio in your assays.
Flexible Scalability
We provide synthesis services ranging from microgram quantities for pilot studies to gram-scale production for extensive in vivo trials.
Expert Technical Support
Our team of Ph.D. level scientists provides end-to-end consultation, from sequence optimization to troubleshooting your transfection experiments.
Integrated Platform
As part of a larger glycobiology and nucleic acid ecosystem, we offer seamless transitions to downstream analysis and modification services.
Frequently Asked Questions
Customer Review
"The EGFP mRNA provided by CD BioGlyco showed significantly higher expression and lower toxicity in our primary neuronal cultures compared to other vendors. The HPLC purification made a noticeable difference in our in vivo studies."
– C.D., Senior Researcher
"Working with CD BioGlyco's team was seamless. Their technical advice on using N1-methylpseudouridine modifications helped us achieve a 5-fold increase in luciferase signal in our DDS evaluation."
– A.G., Project Leader
"We rely on CD BioGlyco for our large-scale reporter mRNA needs. The consistency between batches is excellent, which is critical for our high-throughput screening assays."
- E.V., Director of Discovery
Associated Services
CD BioGlyco is committed to providing the scientific community with the highest quality reporter gene mRNA synthesis service. By combining our expertise in therapeutic oligonucleotide synthesis with cutting-edge technology, we ensure your research is supported by reliable and high-performance tools. Please feel free to contact us for more information about our services or to request a customized quote.
Reference
- N, M.P.A.; et al. Reporter gene-based qRT-PCR assay for Rho-dependent termination in vivo. Cells. 2023, 12(22): 2596. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform


